Current Environment:

Summary

Study AG348-C-003 is a multicenter study designed to evaluate the safety and efficacy of different dose levels of AG-348 (mitapivat) in participants with PK deficiency.

Conditions

Pyruvate Kinase Deficiency

Recruitment Status

Active, not recruiting

Detailed Description

This is a Phase 2, open label, two arm, multicenter, randomized, dose-ranging study during which adult participants with PK deficiency will receive multiple doses of AG-348 for up to 24 weeks (Core Period); eligible participants may enter an Extension Period to receive AG-348 for up to 8 additional years. Data will be reviewed on a regular basis and study design, dose and schedule will be adapted based on these reviews. The study will evaluate the safety and tolerability of multiple doses of AG-348, pharmacokinetic and pharmacodynamic (PD) profile of AG-348 and early indicators of clinical efficacy.

Eligibility Criteria

Inclusion Criteria:

Informed consent
Male or female, aged 18 years and older
Known medical history of PK deficiency
PK deficiency confirmed by enzymatic assay at Screening
Genotypic characterization of PKR gene at Screening
Genotypic characterization of uridine-5'-diphosphate-glucuronyltransferase-A1 (UGTA1) gene to document underlying Gilbert's disease (Gilbert's disease patients are eligible)
Males Hb ≤ 12.0 g/dL, females Hb ≤ 11 g/dL
Transfusion independent, defined as no more than 3 units of red blood cells (RBC) transfused in 12 months prior to the first day of study dosing and no transfusions within 4 months of first day of study dosing
Splenectomized patients must have had the procedure at least 6 months prior to Screening and must be up-to-date in recommended vaccinations
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Must be taking at least 1 mg folic acid daily in the 21 days prior to screening
Adequate organ function defined by liver function, kidney function, platelet count and coagulation assessments
Agreement to use approved contraceptive measures

Women must not be breastfeeding

For entry into the Extension Period, patients must meet criteria # 15-16:

Must have completed 24 weeks of treatment during the Core Period and tolerated AG-348
The treating Investigator agrees that there is a potential for clinical benefit to continued treatment and recommends participation in the Extension Period and the Medical Monitor approves

Exclusion criteria

Hb ˃ 12.0 g/dL if male, Hb ˃11.0 g/dL if female
Additional diagnosis of other congenital or acquired blood disorder
Iron overload sufficiently severe to result in cardiac, hepatic or pancreatic insufficiency
Bone marrow or stem cell transplant
Clinically symptomatic cholelithiasis or cholecystitis
Currently enrolled in any other investigational trial. Participation in the PK Deficiency Natural History Study (NCT02053480) is permitted
Exposure to any investigational drug, device or procedure within 28 days prior to screening or during trial participation
Concurrent medical condition such as poorly controlled hypertension, heart failure, active infection, frequent post-splenectomy sepsis, Hepatitis B or C, Human Immunodeficiency Virus type 1 (HIV1) or Human Immunodeficiency Virus type 2 (HIV2) infection, poorly controlled diabetes mellitus, history of primary malignancy with the exception of curatively treated nonmelanomatous skin cancer, cervical cancer of breast cancer in situ
Major surgery in the last 6 months
Psychiatric disorder that could compromise the ability of the patient to cooperate with the study
Serum bilirubin higher to the upper limit of normal attributable to factors other than hemolysis or Gilbert's Syndrome
Use of restricted products known to strongly inhibit cytochrome P450 (CYP) 3A4 metabolism within 5 days prior to Prior Day 1 dosing, or to strongly induce cytochrome P450 3A4 (CYP3A4) metabolism within 28 days prior to Day 1 dosing, or to strongly inhibit P-glycoprotein transporter within 5 days prior to Day 1 dosing, or digoxin within 5 days prior to Day 1 dosing.
Heart-rate corrected QT interval - Fridericia's method (QTcF) interval ˃ 450 ms in male, QTcF > 470 ms in female, with the exception of patients with a left Bundle Branch Block
Cardiac arrhythmias that are clinically significant or treated with drugs that are substrates of CYP3A4
Allergy to sulfonamides if characterized by acute hemolytic anemia, anaphylaxis, rash of erythema multiforme type or Stevens-Johnson Syndrome
Any other medical or psychological condition deemed by the Investigator to be likely to interfere with a patient's ability to participate in the study
Patients will not be permitted to enter the Extension Period if: The patient experienced AEs during the Core Period that are considered by the treating Investigator or the Sponsor's designated Medical Monitor to pose a significant safety risk to the patient if treatment were to be extended

Intervention

Intervention Type

Intervention Name

Drug

AG-348

Phase

Phase 2

Gender

All

Minimum Age

18 Years

Maximum Age

N/A

Download Date

May 10, 2022

Principal Investigator

N/A

Primary Contact Information

For more information on this trial, visit clinicaltrials.gov.

Contact

For more information and to contact the study team: